Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 456 results for blood monitoring

  1. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  2. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (HTG385)

    Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.

  3. LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)

    NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home

  4. Acumen IQ sensor for predicting hypotension risk (MIB266)

    NICE has developed a medtech innovation briefing (MIB) on Acumen IQ sensor for predicting hypotension risk .

  5. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

  6. Therapeutic hypothermia for acute ischaemic stroke (HTG511)

    Evidence-based recommendations on therapeutic hypothermia for acute ischaemic stroke in adults. This involves using a cooling device to reduce the body’s temperature after a stroke.

  7. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  8. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  9. Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)

    NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .

  10. Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

    Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.

  11. Caesarean birth (QS32)

    This quality standard covers the care of pregnant women or pregnant people who are considering having or may need to have a caesarean birth, including those who have had a caesarean birth in the past. It includes decision making, reducing the risk of complications and care after a caesarean birth. It describes high-quality care in priority areas for improvement.

  12. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

  13. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

  14. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

  15. Intrapartum care (QS105)

    This quality standard covers the care of women and their babies during labour and immediately after the birth. It covers women who go into labour at term, and includes women at low risk of complications during labour and those who go on to develop complications. It describes high-quality care in priority areas for improvement.